NDAORALTABLET
Approved
Oct 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
6/8 — Strong
COMTAN (entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 1999.
Drug data last refreshed 8h ago · AI intelligence enriched 14h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMTAN (entacapone) is an oral catechol O-methyltransferase (COMT) inhibitor approved in 1999 for use as an adjunct to levodopa/carbidopa therapy in Parkinson's disease patients experiencing motor fluctuations. It works by inhibiting the enzyme responsible for breaking down dopamine, thereby extending the duration of levodopa's therapeutic effect and reducing "off" periods.
$0.033BPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D spending ($33K in 2023), COMTAN teams are likely contracting; roles focus on maximizing remaining exclusivity and managing transition to generic.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
Started May 2026
215 enrolled
Advanced Parkinson Disease
Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
Started Jun 2025
216 enrolled
Parkinson Disease (PD)
Pilot Study of Entacapone for Methamphetamine Abuse
Started Jun 2014
29 enrolled
Methamphetamine Dependence
Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens
Started Feb 2011
27 enrolled
Parkinson's Disease
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
Started Aug 2008
0Parkinson's Disease
Worked on COMTAN at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.